Genetics and Treatment of Osteopetrosis Disorders

Osteopetrosis disorders encompass a spectrum of heritable conditions characterised by increased bone density and impaired bone resorption. Genetic analyses have identified mutations in genes essential for osteoclast differentiation and function—such as TCIRG1, CLCN7, OSTM1, PLEKHM1 and SNX10—resulting in phenotypes that range from asymptomatic adult onset to severe neonatal disease with bone marrow failure and neuropathies. The core pathology lies in defective osteoclastogenesis or malfunctioning resorptive mechanisms, manifesting as brittle bones, anaemia, cranial nerve compression and dental anomalies. Allogeneic haematopoietic stem cell transplantation remains the standard therapy, restoring functional osteoclast populations but limited by donor availability and transplant‐related morbidity. Recent advances in gene therapy, targeted molecular interventions and pharmacological modulation of signalling pathways are reshaping therapeutic approaches, fostering personalised treatments and enhanced patient outcomes. Integrative animal models and patient-derived cell studies continue to clarify the interplay between skeletal, haematopoietic and immune systems, guiding the development of non-invasive strategies and preventive protocols. Early genetic diagnosis and multidisciplinary management are critical to mitigate complications and improve quality of life in affected individuals worldwide.

Research from Nature Portfolio

Recent studies have elucidated intracellular mechanisms regulating osteoclast activity and uncovered novel genetic defects in human osteopetrosis. Investigations into CCR5-mediated signalling have shown that this pathway controls centrosome clustering in mature osteoclasts, thereby sustaining directional vesicle trafficking and secretion of cathepsin K. CCR5 disruption altered PLEKHM1 expression and compromised bone matrix resorption, pointing to new targets for restoring osteoclast polarity and function. Foundational work on SNX10 splice-site mutations demonstrated how a truncated protein impedes ruffled border formation and abrogates osteoclast-mediated bone degradation. These insights refine genotype–phenotype correlations and highlight avenues for molecular activation of residual resorptive capacity.

Genetics and Treatment of Osteopetrosis Disorders publication trend

The graph below shows the total number of articles in genetics and treatment of osteopetrosis disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoclast: A specialised multinucleated cell responsible for bone resorption through enzymatic degradation and acid secretion.

Osteoblast: A mononuclear cell that synthesises bone matrix and regulates its mineralisation.

Haematopoietic stem cell transplantation (HSCT): A procedure in which blood-forming stem cells are infused to reconstitute normal haematopoiesis and osteoclast function.

Retinoic acid signalling: A molecular cascade activated by vitamin A metabolites that governs cell differentiation and skeletal development.

Ruffled border: The specialised membrane domain of active osteoclasts where bone matrix degradation occurs.

Lentiviral vector gene therapy: A gene delivery system using engineered lentiviruses to introduce therapeutic genes into target cells.

References

1. Osteopetrosis-like disorders induced by osteoblast-specific retinoic acid signaling inhibition in mice. Bone Research (2024).
2. Correction of osteopetrosis in the neonate oc/oc murine model after lentiviral vector gene therapy and non-genotoxic conditioning. Frontiers in Endocrinology (2024).
3. Centrosome clustering control in osteoclasts through CCR5-mediated signaling. Scientific Reports (2023).
4. SNX10 gene mutation leading to osteopetrosis with dysfunctional osteoclasts. Scientific Reports (2017).
5. Autosomal recessive osteopetrosis: mechanisms and treatments. Disease Models & Mechanisms (2021).
6. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. Journal of Clinical Investigation (2007).